Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul A Sutton

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of Separation Science|April 3, 2007
Analysis of 'ARN' naphthenic acids by high temperature gas chromatography and high performance liquid chromatographyBen E Smith, Paul A Sutton, C Anthony Lewis, et al.
Laboratory Animals|February 15, 2019
Development of an orthotopic syngeneic murine model of colorectal cancer for use in translational researchJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Psycho-Oncology|September 30, 2024
A Preliminary Phenomenological Exploration of Experiences of the Empty Pelvis Syndrome Derived From a Modified-Delphi: The Price of Survival Following Pelvic Exenteration for Advanced Pelvic CancerCharles T West, Andreas Denys, Sam A Rose, et al.
Critical Reviews in Oncology/Hematology|November 13, 2015
From mice to men: Murine models of colorectal cancer for use in translational researchJonathan P Evans, Paul A Sutton, Boleslaw K Winiarski, et al.
International Journal of Radiation Oncology, Biology, Physics|June 12, 2024
Myoferlin: A Potential Marker of Response to Radiation Therapy and Survival in Locally Advanced Rectal CancerHayley Fowler, Rachael E Clifford, David Bowden, et al.
Oncotarget|June 23, 2018
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Oncotarget|February 19, 2019
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Annals of Surgery|May 15, 2024
Defining Benchmarks for Pelvic Exenteration Surgery: A Multicentre Analysis of Patients with Locally Advanced and Recurrent Rectal CancerKilian G M Brown, Michael J Solomon, Cherry E Koh, et al.
Diseases of the Colon and Rectum|October 20, 2025
Conventional Versus High-Complexity Total Pelvic Exenteration for Locally Advanced and Locally Recurrent Rectal Cancer: An International Multicenter StudyCeline Garrett, Kilian G M Brown, Michael J Solomon, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Separation Science|April 3, 2007
Analysis of 'ARN' naphthenic acids by high temperature gas chromatography and high performance liquid chromatographyBen E Smith, Paul A Sutton, C Anthony Lewis, et al.
Laboratory Animals|February 15, 2019
Development of an orthotopic syngeneic murine model of colorectal cancer for use in translational researchJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Psycho-Oncology|September 30, 2024
A Preliminary Phenomenological Exploration of Experiences of the Empty Pelvis Syndrome Derived From a Modified-Delphi: The Price of Survival Following Pelvic Exenteration for Advanced Pelvic CancerCharles T West, Andreas Denys, Sam A Rose, et al.
Critical Reviews in Oncology/Hematology|November 13, 2015
From mice to men: Murine models of colorectal cancer for use in translational researchJonathan P Evans, Paul A Sutton, Boleslaw K Winiarski, et al.
International Journal of Radiation Oncology, Biology, Physics|June 12, 2024
Myoferlin: A Potential Marker of Response to Radiation Therapy and Survival in Locally Advanced Rectal CancerHayley Fowler, Rachael E Clifford, David Bowden, et al.
Oncotarget|June 23, 2018
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Oncotarget|February 19, 2019
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Annals of Surgery|May 15, 2024
Defining Benchmarks for Pelvic Exenteration Surgery: A Multicentre Analysis of Patients with Locally Advanced and Recurrent Rectal CancerKilian G M Brown, Michael J Solomon, Cherry E Koh, et al.
Diseases of the Colon and Rectum|October 20, 2025
Conventional Versus High-Complexity Total Pelvic Exenteration for Locally Advanced and Locally Recurrent Rectal Cancer: An International Multicenter StudyCeline Garrett, Kilian G M Brown, Michael J Solomon, et al.
Pageof 5